Recruiting
Phase 3

Lumateperone

Sponsor:

Intra-Cellular Therapies, Inc.

Code:

NCT06372964

Conditions

Bipolar Depression

Eligibility Criteria

Sex: All

Age: 10 - 17

Healthy Volunteers: Not accepted

Interventions

Lumateperone

Placebo

Study Details

Brief summary:

This is a multicenter, randomized, double-blind, placebo-controlled study in pediatric patients who are experiencing major depressive episodes (MDEs) associated with a primary diagnosis of bipolar I or bipolar II disorder as confirmed by Kiddie Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL), according to criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM 5).

Conditions

Bipolar Depression

Study ID

NCT06372964

Start date

May 13, 2024

Status verified date

Jul, 2025

Completion date

May, 2027

Anticipated

Primary completion date

Apr, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 10 - 17

Healthy Volunteers: Not accepted

Inclusion Criteria:

1. Able to provide consent as follows:

  • The Legally Authorized Representative (LAR) must provide written, informed consent.
  • The patient must provide written assent;
2. Male or female patients 10 to 17 years of age, inclusive;
3. Have a Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition Text Revision (DSM-5-TR) primary diagnosis of bipolar I or bipolar II disorder with a current MDE without psychosis as confirmed by Kiddie Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL);
4. Subject has a lifetime history of at least one manic or hypomanic episode.
5. Subject's current major depressive episode is ≥ 4 weeks and less than 12 months in duration;
6. CDRS-R total score ≥ 45 with ≥ 5 on Item 11 (depressed feelings) at Screening and Baseline;
7. Young Mania Rating Scale (YMRS) score ≤ 15 (with YMRS Item 1 \[elevated mood\] score ≤ 2) at Screening and Baseline.

Exclusion Criteria:

1. Has a primary psychiatric diagnosis other than bipolar I or bipolar II disorder. Exception includes:

  • Attention deficit hyperactivity disorder (ADHD). If a subject is taking medications for ADHD, they must have been on a stable treatment regimen of these medication(s) for 30 days prior to screening and the treatment regimen is expected to remain stable throughout the study.
2. Intellectual disability based on Investigator opinion and DSM-5 criteria
3. Patient has been hospitalized for a bipolar manic episode within the 30 days prior to randomization;
4. Demonstrates a ≥ 25% decrease (improvement) in the CDRS-R total score between Screening and Baseline visits, or the CDRS-R is below 45 at Baseline;
5. In the opinion of the Investigator, the patient has a significant risk for suicidal behavior during his/her participation in the study or

1. At Screening, the patient scores "yes" on Suicidal Ideation Items 3, 4, or 5 of the Columbia-Suicide Severity Rating Scale (C-SSRS) within 6 months prior to Screening or, at Baseline, the patient scores "yes" on Suicidal Ideation Items 3, 4, or 5 since the Screening Visit;
2. At Screening, the patient has had 1 or more suicidal attempts within the 2 years prior to Screening; or
3. At Screening or Baseline, scores > 3 on Item 13 (suicidal ideation) on the CDRS-R; or
4. The patient is considered to be an imminent danger to him/herself or others.

Study Design

Enrollment

384 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Lumateperone

Lumateperone 42 mg for patient ages 13-17 years and Lumateperone 21 mg for patient ages 10-12 years.

placebo comparator: Placebo

Matching placebo

Interventions

Lumateperone

Lumateperone administered orally, once daily.

Placebo

Matching placebo administered orally, once daily.

Primary outcome measure

  • Children's Depression Rating Scale-Revised (CDRS-R) [ Time Frame: Week 6 ]

Central Contacts and Locations

Central contacts

Locations

Clinical Site

Recruiting

Dothan, Alabama, United States, 36303

Clinical Site

Recruiting

Little Rock, Arkansas, United States, 72204

Clinical Site

Recruiting

Anaheim, California, United States, 92805

Clinical Site

Recruiting

Redlands, California, United States, 92373

Clinical Site

Recruiting

San Diego, California, United States, 92103

Clinical Site

Recruiting

West Covina, California, United States, 91790

Clinical Site

Recruiting

Colorado Springs, Colorado, United States, 80910

Clinical Site

Recruiting

Hialeah, Florida, United States, 33012

Clinical Site

Recruiting

Homestead, Florida, United States, 33030

Clinical Site

Recruiting

Miami, Florida, United States, 33122

Clinical Site

Recruiting

Miami, Florida, United States, 33125

Clinical Site

Recruiting

Miami, Florida, United States, 33130

Clinical Site

Recruiting

Miami, Florida, United States, 33134

Clinical Site

Recruiting

Miami, Florida, United States, 33144

Clinical Site

Recruiting

Miami, Florida, United States, 33165

Clinical Site

Recruiting

Miami, Florida, United States, 33173

Clinical Site

Recruiting

Miami, Florida, United States, 33176

Clinical Site

Recruiting

Miami, Florida, United States, 33186

Clinical Site

Recruiting

Miami Gardens, Florida, United States, 33056

Clinical Site

Recruiting

Miami Lakes, Florida, United States, 33014

Clinical Site

Recruiting

Miami Lakes, Florida, United States, 33016

Clinical Site

Recruiting

Miami Springs, Florida, United States, 33166

Clinical Site

Recruiting

Orlando, Florida, United States, 32803

Clinical Site

Recruiting

West Palm Beach, Florida, United States, 33407

Clinical Site

Recruiting

Atlanta, Georgia, United States, 30318

Clinical Site

Recruiting

Decatur, Georgia, United States, 30030

Clinical Site

Recruiting

Lawrenceville, Georgia, United States, 30046

Clinical Site

Recruiting

Savannah, Georgia, United States, 31405

Clinical Site

Recruiting

Indianapolis, Indiana, United States, 46202

Clinical Site

Recruiting

Bloomfield Hills, Michigan, United States, 48302

Clinical Site

Recruiting

Saint Charles, Missouri, United States, 63304

Clinical Site

Recruiting

Lincoln, Nebraska, United States, 68526

Clinical Site

Recruiting

Avon Lake, Ohio, United States, 44012

Clinical Site

Recruiting

Cincinnati, Ohio, United States, 45219

Clinical Site

Recruiting

Garfield, Ohio, United States, 44125

Clinical Site

Recruiting

Westlake, Ohio, United States, 44145

Clinical Site

Recruiting

Oklahoma City, Oklahoma, United States, 73112

Clinical Site

Recruiting

Oklahoma City, Oklahoma, United States, 73116

Clinical Site

Recruiting

Austin, Texas, United States, 78759

Clinical Site

Recruiting

Flower Mound, Texas, United States, 76028

Clinical Site

Recruiting

Houston, Texas, United States, 77089

Clinical Site

Recruiting

Houston, Texas, United States, 77090

Clinical Site

Recruiting

Richmond, Texas, United States, 77407

Clinical Site

Recruiting

Richmond, Virginia, United States, 23220

Clinical Site

Recruiting

Bellevue, Washington, United States, 98007

Clinical Site

Recruiting

Everett, Washington, United States, 98201

More Information

Sponsor

Intra-Cellular Therapies, Inc.

Last update posted

Jul 8, 2025

Last verified

Jul, 2025

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-19. This information was provided to ClinicalTrials.gov by Intra-Cellular Therapies, Inc. on 2025-07-08.